Related Experiment Video
Updated: Apr 28, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
ASC-J9 suppresses renal cell carcinoma progression by targeting an androgen receptor-dependent HIF2α/VEGF signaling
Dalin He1, Lei Li2, Guodong Zhu1
1Sex Hormone Research Center, Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Abstract:
Males have a higher incidence of renal cell carcinoma (RCC) than females, but the reason for this gender difference is unknown. Addressing this question, we report the discovery of an androgen receptor (AR)-induced HIF2α/VEGF signal that drives RCC progression. AR attenuation or augmentation in RCC cells altered their proliferation, migration, and invasion in multiple models in vitro and in vivo. Mechanistic investigations revealed that AR targeting inhibited RCC cell migration and invasion by modulating HIF2α/VEGF signals at the level of mRNA and protein expression. Interrupting HIF2α/VEGF signals with inhibitors of either HIF2α or VEGF was sufficient to suppress RCC progression. Similarly, the specific AR degradation enhancer ASC-J9 was sufficient to suppress AR-induced HIF2α/VEGF signaling and RCC progression in multiple models in vitro and in vivo. Taken together, our results revealed a novel role for AR in RCC initiation and progression with implications for novel therapeutic strategies.
Insights
Men develop more kidney cancer (renal cell carcinoma, RCC) than women. This study found that the androgen receptor (AR) activates a HIF2α/VEGF pathway, driving RCC progression and offering new therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Urology
Background:
- Renal cell carcinoma (RCC) exhibits a higher incidence in males compared to females.
- The underlying biological mechanisms for this observed gender disparity remain largely unknown.
Purpose of the Study:
- To investigate the role of the androgen receptor (AR) in driving renal cell carcinoma (RCC) progression.
- To elucidate the molecular signaling pathways involved in AR-mediated RCC development.
- To identify potential therapeutic targets for mitigating gender-specific RCC progression.
Main Methods:
- Utilized in vitro and in vivo models of RCC to assess the impact of AR modulation on cancer cell behavior.
- Investigated the effects of AR attenuation and augmentation on RCC cell proliferation, migration, and invasion.
- Analyzed the modulation of HIF2α/VEGF signaling at both mRNA and protein levels in response to AR targeting.
- Evaluated the efficacy of HIF2α/VEGF inhibitors and the AR degradation enhancer ASC-J9 in suppressing RCC progression.
Main Results:
- Androgen receptor (AR) activity was found to induce a HIF2α/VEGF signaling pathway crucial for RCC progression.
- Modulation of AR levels significantly affected RCC cell proliferation, migration, and invasion in various experimental models.
- Targeting AR inhibited RCC cell migration and invasion by regulating HIF2α/VEGF signaling at the molecular level.
- Inhibition of HIF2α or VEGF, as well as the AR degrader ASC-J9, effectively suppressed RCC progression in vitro and in vivo.
Conclusions:
- Discovered a novel role for the androgen receptor (AR) in the initiation and progression of renal cell carcinoma (RCC).
- The AR-induced HIF2α/VEGF signaling pathway represents a critical mechanism underlying male predominance in RCC.
- These findings suggest promising novel therapeutic strategies targeting the AR-HIF2α/VEGF axis for RCC treatment.
More Related Videos
11:27Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
Regulation of Angiogenesis and Blood Supply
Abnormal Proliferation
PI3K/mTOR/AKT Signaling Pathway
Experimental RNAi